Page 81 - Fall2020

federal grants to experiment on human fetal tis- price she would charge him for human organs. 64
sue. The business has become so lucrative that As further evidence of what Smith described, scientists responsible
63
one undercover CMP video featured a Planned for developing the newer Walvax-2 fetal cell line have openly noted how
Parenthood director saying “I want a Lambor- they induced labor using “water bag” abortion techniques. The purpose
ghini” as she haggled with Daleiden over the was to shorten the delivery time and prevent the death of the fetus,

COVID VACCINE CONCERNS
The race to develop a coronavirus vaccine has been running at lightning speed since the SARS-CoV-2 virus was
named as the purported cause of Covid-19 illness in January 2020. As of late August, researchers around the world
were in the process of developing more than one hundred sixty-five vaccines. Thirty-two of these coronavirus vaccine
candidates are currently in human trials, two of which have already been approved for early or limited use. 68,69 In Russia,
President Vladimir Putin announced approval of a vaccine on August 11, initially to be given only to “a small number of
citizens from vulnerable groups,” including medical personnel and the elderly. 70
Under normal circumstances, vaccine development requires a testing process that can take a minimum of five to
six years and sometimes decades, and even then scientists cut important corners such as not using inert placebos. The
71
general stages of the development cycle begin with preclinical testing where scientists give the vaccine to animals. This is
followed by Phase One safety trials in a small number of human volunteers to test safety and dosage as well as confirm
that the vaccine stimulates the production of antibodies. In expanded Phase Two trials, typically involving hundreds of
participants, scientists assess whether the vaccine’s effects vary by age group (e.g., children, the elderly) or other factors
such as health status. Finally, Phase Three trials are meant to determine the vaccine’s safety and efficacy when given to
thousands of people over a specified length of time. 72
Of grave concern is the fact that Covid-19 vaccine developers are compressing standard timelines. Many are forgo-
ing animal studies. Russia’s vaccine, Sputnik V, was given approval after testing in only seventy-six people, well before
Phase Three trials had even begun. 70,73 China approved experimental use of a coronavirus vaccine in selected “high-risk”
74
groups in late July, without any clinical trial results. These premature authorizations could have dire implications, espe-
cially considering the fact that previous attempts at developing comparable vaccines have triggered lethal hyperimmune
reactions in vaccinated animals or children who later came in contact with the wild virus. This immune backfiring, or
“pathogenic priming,” is the reason that no vaccine has ever been approved for the common cold or the coronaviruses
75
associated with Middle Eastern Respiratory Syndrome (MERS) and Sudden Acute Respiratory Syndrome (SARS).
Regrettably vaccine manufacturers have a strong incentive to win the Covid-19 vaccine race, despite the failure of
previous attempts. Companies have the potential to earn billions of dollars once their vaccine goes to market, and some
have already profited substantially through stock evaluations. Moderna, a company that has never brought a vaccine
or any other drug to market, saw its stock price rise fourfold virtually overnight based on coronavirus vaccine specula-
tion. Additionally the federal government is granting billions of dollars to expedite the development of a coronavirus
76
vaccine. For example, Moderna received nearly one billion dollars, and Novavax received 1.6 billion dollars in federal
77
funding. To date, the White House has committed twelve billion dollars to six vaccine candidates under its Operation
78
Warp Speed vaccine plan. Wealthy nations have struck deals to purchase a total of more than two billion doses of a
79
coronavirus vaccine that has yet to be proven either safe or effective.
80
In the U.S., vaccine manufacturers have full immunity from all liability for any potential injuries or deaths through
a declaration under the Public Readiness and Emergency Preparedness (PREP) Act. So even though companies and
81
governments are fast-tracking the vaccines—and some manufacturers, like Moderna, are using highly experimental and
potentially dangerous RNA or DNA technologies—citizens will not be able to sue if a Covid-19 vaccine harms them.
Even supposing that a never-before-used experimental technology could produce a “safe” vaccine, one must also
ask how long such a vaccine would be effective, considering that the coronavirus appears to be “mutating.” This begs
82
an important question: will manufacturers have to chase down the mutations and retool their Covid-19 vaccines annu-
ally, using the same guesswork involved in manufacturing each year’s poorly performing influenza vaccine?
A June poll found that only about half of Americans reported that they planned to get a Covid-19 vaccine. The
83
remainder were either unsure (31 percent) or planned to decline (20 percent). Perhaps this is because they know that
84
systemic adverse reactions are common among Covid-19 vaccine trial participants. The most important question may
be: are you willing to get a vaccine brought to market at unprecedented speed for a virus that is mutating and primarily
has affected older individuals who already had serious health problems? If your answer is no, call your representa-
85
tives today and let them know you are against a mandated coronavirus vaccine. If we do not make our voices heard,
mandates are sure to follow.

FALL 2020 Wise Traditions 79